Newly developed retatrutide, a twin -action medication targeting simultaneously GLP-1 and GIP receptors, is creating considerable interest within the weight loss community. Preliminary clinical research have revealed substantial losses in overall mass and gains in metabolic markers for individuals with excess weight . Researchers believe this nove